New Biomarker Assay Detects Neuroblastoma With Greater Sensitivity
Improved disease assessment aids in prediction of relapse in children
Investigators at The Saban Research Institute of Children’s Hospital Los Angeles have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease. In a study, led by Araz Marachelian, MD, of the Children’s Center for Cancer and Blood Diseases, researchers provide the first systematic comparison of standard imaging evaluations versus the new assay that screens for five different neuroblastoma-associated genes and determine that the new assay improves disease assessment and provides prediction of disease progression. Neuroblastoma is a cancer of the nervous system that exists outside the brain and typically is diagnosed in children five years or age or younger. Forty-five percent of patients have high-risk, metastatic tumors (stage 4) when diagnosed.
Click here to read more.
18th Congress of International Society of Craniofacial Surgery
Sept. 16-19, 2019; Paris
2019 Neuroscience and Psychiatry Conference
Sept. 19-20, 2019; Singapore
2019 Managing Coding and Reimbursement Challenges
Sept. 19-21, 2019; Austin, Texas